Dubai, July 6th, 2017
Genpharm announced today the launch of a Primary Care Unit for the Middle East Region
This new Business Unit will be managed independently through a fully fledge organizational structure, dedicated and experienced staff.
Genpharm started its regional operations in late 2012 with a focused approach on Rare Disease and Specialty Therapeutics. This year Genpharm’s leadership in the Orphan space has been cemented with several new partnerships. “Companies have trusted our expertise and the way we conduct our operations with the highest standards”, says Karim Smaira. “The Pharmaceutical markets in the region are very dynamic and have witnessed a rapid evolution. One of the key trends has been the portfolio review by the major manufacturers leading to several collaboration agreements. The direct approach by some of these players has prompted Genpharm’s interest resulting in the creation of this new Business Unit”.
“With this new expansion, we remain loyal to our Vision and to our overall strategy that has proven successful. We continue striving to be the partner of choice for pharmaceutical companies, looking to expand into the MENA region. Regardless of the business unit or the indication, we trust that our culture, the quality of the staff and the supporting processes will continue to be our driving force”, concurs Kamel Ghammachi. “ We will shortly be making an announcement about the Primary Care product portfolio.
Dr. Khaled Abdul Fattah has been appointed to lead Genpharm’s new Primary Care Unit. With his 18 years career in Multinational companies such as Novartis, Sanofi, and Servier, Khaled brings an extensive regional experience. He has held several marketing and sales positions spanning the Primary Care and Transplant businesses.